ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,127.79
      1.26%
      US Tech 100
      17,446.00
      2.17%
      Dow Jones
      38,675.68
      1.18%
      Brent Oil
      82.765
      0.00%
      Bitcoin
      64,338.34
      0.70%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. Protara Therapeutics Inc (TARA)

      7. Protara Therapeutics Inc (TARA) News

      TARA

      Protara Therapeutics (TARA)

      Protara Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:TARA
      DateTimeSourceHeadlineSymbolCompany
      05/02/20248:00AMGlobeNewswire Inc.Protara Therapeutics Announces First Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:TARAProtara Therapeutics Inc
      04/05/20248:04AMGlobeNewswire Inc.Protara Therapeutics Announces Oversubscribed $45 Million Private Placement FinancingNASDAQ:TARAProtara Therapeutics Inc
      04/05/20248:02AMGlobeNewswire Inc.Protara Therapeutics Announces Alignment with FDA on Registrational Path Forward for IV Choline Chloride in Patients Dependent on Parenteral NutritionNASDAQ:TARAProtara Therapeutics Inc
      04/05/20248:00AMGlobeNewswire Inc.Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBCNASDAQ:TARAProtara Therapeutics Inc
      03/13/20248:00AMGlobeNewswire Inc.Protara Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business UpdateNASDAQ:TARAProtara Therapeutics Inc
      02/28/20248:00AMGlobeNewswire Inc.Protara Therapeutics to Present at the TD Cowen 44th Annual Health Care ConferenceNASDAQ:TARAProtara Therapeutics Inc
      01/23/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
      01/23/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
      01/23/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
      01/23/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
      01/23/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
      01/12/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
      01/12/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
      01/12/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
      01/05/20244:35PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
      01/05/20244:30PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
      01/05/20244:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
      11/30/20238:30AMGlobeNewswire Inc.Protara Therapeutics Announces Presentation of Additional Encouraging Data from Phase 1a ADVANCED-1 Trial of TARA-002 in NMIBC at the 24th Annual Meeting of the Society of Urologic OncologyNASDAQ:TARAProtara Therapeutics Inc
      11/15/202312:15AMEdgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:TARAProtara Therapeutics Inc
      11/03/20238:31AMEdgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:TARAProtara Therapeutics Inc
      11/03/20238:20AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TARAProtara Therapeutics Inc
      11/03/20238:10AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARAProtara Therapeutics Inc
      11/03/20238:00AMGlobeNewswire Inc.Protara Therapeutics Announces Third Quarter 2023 Financial Results and Business UpdateNASDAQ:TARAProtara Therapeutics Inc
      10/23/20238:00AMGlobeNewswire Inc.Protara Therapeutics Announces Dosing of First Patient in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic MalformationsNASDAQ:TARAProtara Therapeutics Inc
      09/20/20238:30AMGlobeNewswire Inc.Protara Therapeutics Announces Dosing of First Patient in Phase 1b/2 ADVANCED-2 Trial of TARA-002 in NMIBC Patients with High Grade Carcinoma in SituNASDAQ:TARAProtara Therapeutics Inc
      09/05/20237:30AMGlobeNewswire Inc.Protara Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:TARAProtara Therapeutics Inc
      08/03/20238:20AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TARAProtara Therapeutics Inc
      08/03/20238:12AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:TARAProtara Therapeutics Inc
      08/03/20238:00AMGlobeNewswire Inc.Protara Therapeutics Announces Second Quarter 2023 Financial Results and Business UpdateNASDAQ:TARAProtara Therapeutics Inc
      07/18/20234:05PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TARAProtara Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:TARA